Search clinical trials for: Deferasirox DFX, FCT

Total 5095 results

Novartis Pharmaceuticals

Completed

Combination Study of Deferasirox and Erythropoietin in Patients With Low- and Int-1-risk Myelodysplastic Syndrome.

Low and Int 1-risk Myelodysplastic Syndrome

Germany, Canada, Korea, Republic of, Sweden, Spain, China, Argentina, Italy, United Kingdom, Algeria
Ain Shams University

Unknown

Study Of Efficacy,Safety of Combined Deferasirox and Deferiprone Versus Combined Deferiprone and Desferal In Conditions of Iron Overload

Sickle Cell Disease | Beta-thalassemia Major | Iron Hemosiderosis

Egypt
Ain Shams University

Unknown

Role of Vitamin C to Augment Iron Chelation With DFP or DFX

Thalassemia Major | Iron Chelation | Vitamin c

Egypt
China Medical University Hospital

Completed

Clinical Trial of Deferasirox Combination Treatment With Deferiprone In Thalassaemia Patients

Beta-thalassemia Major
Novartis Pharmaceuticals

Completed

Evaluating Use of Deferasirox as Compared to Deferoxamine in Treating Cardiac Iron Overload (CORDELIA)

Transfusional Hemosiderosis | Transfusional Iron Overload

Taiwan, Turkey, Egypt, United Kingdom, Thailand, Canada, China, Italy, Cyprus, Lebanon, United Arab Emirates
Consorzio per Valutazioni Biologiche e Farmacologiche
European Commission

Completed

Efficacy/Safety Study of Deferiprone Compared to Deferasirox in Paediatric Patients

Chronic Iron Overload

Italy, United Kingdom, Egypt, Greece, Cyprus, Albania, Tunisia
Novartis Pharmaceuticals

Completed

Open-label, Multicenter Study Assessing Preference for Deferasirox Film-coated Tablet Compared to Dispersible Tablet (Jupiter)

Non-transfusion-dependent Thalassemia | Transfusion-dependent Thalassemia

Egypt, Turkey, Thailand, Lebanon, Morocco, Saudi Arabia, Vietnam
Elliott Vichinsky

Completed

Combined Chelation Therapy in Patients With Transfusion Dependent Thalassemia and Iron Overload

Iron Overload | Thalassemia

United States
Novartis Pharmaceuticals

Completed

Study to Evaluate the Efficacy and Safety of Deferasirox Film-coated Tablet Versus Phlebotomy in Patients With Hereditary Hemochromatosis (HH)

Hereditary Hemochromatosis

Belgium, France, Russian Federation, Romania, Slovakia, Spain, Switzerland
Merck Sharp & Dohme LLC

Completed

A Study of the Pharmacokinetics of Two Formulations of MK-1006 (MK-1006-010 AM1)(COMPLETED)

Type 2 Diabetes
Novartis Pharmaceuticals

Completed

Study of Deferasirox Relative to Subcutaneous Deferoxamine in Sickle Cell Disease Patients

Iron Overload | Sickle Cell Disease | Hemolytic Anemia

United States, Canada
Novartis Pharmaceuticals

Completed

Phase II Study to Investigate the Benefits of an Improved Deferasirox Formulation (Film-coated Tablet)

Chronic Iron Overload Due to Transfusion-dependant Anemias

Italy, Austria, Thailand, Spain, Germany, Mexico, Malaysia, Greece, United Kingdom, France, Saudi Arabia, United Arab Emirates, Lebanon, Russian Federation, United States, Argentina
Fundació Institut de Recerca de l'Hospital de la...

Unknown

Comparative Study About the Impact of Two Oil Emulsions Administered Intravenously on Severe Acute Pancreatitis

Severe Acute Pancreatitis

Spain
Sichuan Academy of Medical Sciences
Peking Union Medical College Hospital

Completed

Early Enteral Nutrition for Severe Acute Pancreatitis

Acute Necrotizing Pancreatitis

China
Novartis Pharmaceuticals

Terminated

Safety and Efficacy of Deferasirox in Combination With Desferoxamine in β-thalassaemia Patients With Severe Cardiac Iron Overload

Cardiac Iron Overload | Transfusion-dependent β-thalassemia Patients

Greece
Novartis Pharmaceuticals

Completed

Study to Evaluate Treatment Compliance, Efficacy and Safety of an Improved Deferasirox Formulation (Granules) in Pediatric Patients (2-<18 Years Old) With Iron Overload

Transfusion-dependent Anemia

Egypt, Hungary, Turkey, United States, Bulgaria, Italy, Belgium, Russian Federation, Philippines, France, Malaysia, India, Oman, Panama, Lebanon, Thailand, Tunisia
Wei Zhou

Unknown

Parenteral Fish Oil in Major Laparoscopic Abdominal Surgery

Liver Tumor | Gastric Tumor | Pancreatic Tumor

China
DisperSol Technologies, LLC

Completed

Pilot Study to Assess the Safety, PK and Iron Chelating Activity of DST-0509 (Deferasirox) in Thalassemia Patients Refractory to Chelation

Thalassemia Major

Thailand, United States
Medical College of Wisconsin

Recruiting

Conditional Cash Transfer Intervention to Improve T2DM (DMCT)

Type 2 Diabetes

United States
University of British Columbia
Mitacs

Completed

Cognitive Brain Training in Older Adults

Mild Cognitive Impairment

Canada
University of Coimbra

Completed

Low Intensity Internet Therapy for Chronic Illness (@LIIT.CI)

Chronic Medical Conditions

Portugal
Novartis Pharmaceuticals

Withdrawn

Effect of Deferasirox on Endocrine Complications in Subjects With Transfusion Dependent Thalassemia (CENTAurus)

Thalassemia (Transfusion Delendent)
Weill Medical College of Cornell University

Unknown

Iron Balance Study of Deferasirox, Deferoxamine and the Combination of Both

Thalassemia

United States
Massachusetts General Hospital

Not yet recruiting

A Comparative Clinical Study to Assess Pain Score and Wound Healing Following Fractional Ablation With a DFG Laser and CO2 Laser

Healthy

United States
VA Office of Research and Development
VA Palo Alto Health Care System

Active, not recruiting

Thriving in the Midst of Moral Pain: The Acceptability and Feasibility of Acceptance and Commitment Therapy for Moral Injury (ACT-MI) Among Warzone Veterans

Moral Injury

United States
Assistance Publique - Hôpitaux de Paris
Association pour l'Etude des Fonctions Digestives (AEFD)

Unknown

Safety and Efficacy of Oral Deferasirox in Patients With Porphyria Cutanea Tarda

Porphyria Cutanea Tarda

France
Azienda Ospedaliera V. Cervello

Completed

Efficacy Study of the Use of Sequential DFP-DFO Versus DFP (SEQDFPDFO)

Beta-Thalassemia | Thalassemia Major

Italy
Uppsala University
Örebro University, Sweden; Uppsala University Hospital; Karlstad University

Completed

Psychological Treatment Targeting Acceptance and Compassion in Chronic Pain Patients

Chronic Pain | Self-Criticism

Sweden
Novartis

Completed

A Study of Long-term Treatment With Deferasirox in Patients With Beta-thalassemia and Transfusional Hemosiderosis

Beta-Thalassemia | Hemosiderosis

Egypt, Lebanon, Oman, Saudi Arabia, Syrian Arab Republic
Novartis Pharmaceuticals

Completed

Efficacy and Safety Study of Deferasirox in Patients With Non-transfusion Dependent Thalassemia (THETIS)

Non-transfusion Dependent Thalassemia

Thailand, Turkey, Italy, Greece, China, United Kingdom, Lebanon, Tunisia
City of Hope Medical Center

Terminated

Deferasirox for Treating Patients Who Have Undergone Allogeneic Stem Cell Transplant and Have Iron Overload

Primary Myelofibrosis | Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Iron Overload | Chronic Myelomonocytic Leukemia | Recurrent Adult Acute Myeloid Leukemia | Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell... and other conditions

United States
Crolll Gmbh
University of Magdeburg; Estimate, GmbH

Completed

The Impact of Deferasirox on Non-Alcoholic-Steatohepatitis (DEFINE)

Non-alcoholic Steatohepatitis | Increased Iron Storage / Disturbed Distribution

Germany
Novartis Pharmaceuticals

Completed

Palatability and Tolerability of Deferasirox Taken With Meals, With Different Liquids or Crushed and Added to Food

Transfusional Hemosiderosis

United States
Novartis Pharmaceuticals

Completed

Safety and Efficacy of Deferasirox (ICL670) in Patients With Iron Overload Resulting From Hereditary Hemochromatosis

Iron Overload | Hereditary Hemochromatosis

United States, Germany, Italy, Australia, Canada, France
The Hospital for Sick Children
Labatt Family Heart Centre; Trainee award through Ontario Student Opportunity...

Completed

Dietary Treatment of Infants With Chylothorax

Chylothorax

Canada
Masonic Cancer Center, University of Minnesota

Terminated

Deferasirox in Treating Patients With Iron Overload After Undergoing a Donor Stem Cell Transplant

Lymphoma | Myelodysplastic Syndromes | Leukemia | Breast Cancer | Iron Overload | Ovarian Cancer | Neuroblastoma | Multiple Myeloma and Plasma Cell Neoplasm

United States
Novartis Pharmaceuticals

Completed

Evaluating the Efficacy of Deferasirox in Transfusion Dependent Chronic Anaemias (Myelodysplastic Syndrome, Beta-thalassaemia Patients) With Chronic Iron Overload

Myelodysplastic Syndromes | Beta-Thalassemia

Hungary
Academisch Medisch Centrum - Universiteit van Amsterdam...

Completed

Low Dose Iron Chelation as TReatment of Oxidative Damage in Sickle Cell Disease (TROS)

Sickle Cell Disease

Netherlands
Abramson Cancer Center of the University of Pennsylvania

Completed

Pilot Study to Assess Hematologic Response in Patients With Acute Myeloid Leukemia or High Risk Myelodysplastic Syndromes Undergoing Monotherapy With Exjade (Deferasirox)

High Risk MDS or AML Patients

United States
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Deferasirox in Patients With Myelodysplastic Syndrome and Transfusion-dependent Iron Overload

Myelodysplastic Syndromes | Transfusion Dependent Iron Overload

Germany
Novartis

Completed

Magnetic Resonance Imaging (MRI) Assessments of the Heart and Liver Iron Load in Patients With Transfusion Induced Iron Overload

Myelodysplastic Syndromes | Hemoglobinopathies | Diamond-Blackfan Anemia | Transfusional Iron Overload | Other Inherited or Acquired Anaemia | MPD Syndrome | Other Rare Anaemias

Australia
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Deferasirox in Patients With Chronic Anemia and Transfusional Hemosiderosis

Transfusional Hemosiderosis | Chronic Anemia

Japan, Turkey, Spain, Poland, Singapore
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Deferasirox in Non-transfusion Dependent Thalassemia Patients With Iron Overload and a One Year Open-label Extension Study (THALASSA)

Non-transfusion Dependent Thalassemia

Greece, Taiwan, Italy, United Kingdom, Lebanon, Turkey, Malaysia, Thailand, United States
Children's Hospital Los Angeles
Novartis Pharmaceuticals

Terminated

Clinical Importance of Treating Iron Overload in Sickle Cell Disease

Anemia, Sickle Cell | Transfusion Hemosiderosis

United States
Novartis Pharmaceuticals

Completed

Observation of Patients With Transfusional Hemosiderosis Treatment With Deferasirox

Transfusional Hemosiderosis

Egypt, Spain, United Kingdom, Jordan
Novartis Pharmaceuticals

Completed

Open-Label Single-Arm Pilot Study in Adult Allogeneic Hematopoietic Stem Cell Transplant Recipients With Transfusional Iron Overload

Iron Overload

Spain
Oregon Health and Science University

Completed

Ghrelin Regulation and Structure: Effect of Diet Composition on Ghrelin

Obesity

United States
Novartis Pharmaceuticals

Completed

Safety and Efficacy of Desferasirox in Chinese Patients With Iron Overload and Aplastic Anemia

Iron Overload

China
Rutgers, The State University of New Jersey

Recruiting

Refinements of Functional Communication Training

Aggression | Self-injurious Behavior

United States
B. Braun Medical SA

Terminated

ICULIP, Influence of Two Lipid Emulsions in the Nosocomial Infection in Critical Patients (ICULIP)

Critical Illness

Spain

Search clinical trials for: Deferasirox DFX, FCT

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in France

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations